Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative antiviral therapy trial in hepatitis B-related hepatocellular carcinoma
ChiCTR1800019166Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of entecavir and tenofovir in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (4 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Biochemical response and Virological response. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
entecavirtenofovir
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR1800019166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019166.